Herombopag for low platelets caused by T‑DM1 in breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm Phase 2 trial planned to enroll about 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia during prior T‑DM1 treatment but whose platelet counts recovered to between 100 and 200 × 10^9/L before the next cycle. Enrolled patients will receive oral herombopag while continuing at least two additional scheduled T‑DM1 cycles, with regular blood counts and safety monitoring. The study will record whether herombopag prevents recurrent thrombocytopenia, reduces treatment delays or dose reductions, and is tolerable in this setting. Safety signals and treatment continuity measures will guide conclusions about utility for managing T‑DM1–related platelet reduction.

Why it matters

Who can join: the full rules

Inclusion：

* Age 18-75 years, any gender;
* Pathologically diagnosed with breast cancer based on histological or cytological examination, and previously treated with neoadjuvant anti-HER-2 therapy followed by T-DM1 adjuvant therapy;
* Experienced grade 2 or higher tumor treatment-related thrombocytopenia during the previous T-DM1 treatment cycle, with platelet count restored to ≥100 × 109/L and ≤200 × 109/L prior to the next treatment;
* ECOG performance status score: 0-2;
* Planned to undergo at least two additional treatment cycles including T-DM1 administration, with the dose of T-DM1 in the current cycle consistent with the previous cycle;
* Expected survival of ≥12 weeks and able to tolerate the current treatment regimen for at least two cycles or more;
* Expected to have good compliance, able to follow up on treatment efficacy and adverse reactions as required by the protocol.

Exclusion:

* A history of other malignant tumors diagnosed within the past 3 years;
* Patients with mental or neurological disorders who are unable to cooperate;
* Patients who are scheduled to undergo or have previously undergone organ or bone marrow transplantation;
* Patients with hematopoietic system disorders other than chemotherapy-induced thrombocytopenia (CTIT), including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, and myelodysplastic syndrome;
* Patients with a history of any arterial or venous thrombotic events within the past 6 months prior to screening;
* Severe bleeding manifestations within 2 weeks prior to screening, such as gastrointestinal or central nervous system bleeding;
* Participation in a clinical trial of the same type of drug within 4 weeks prior to enrollment;
* Pregnant or lactating women;
* Patients with a history of hypersensitivity to the study drug;
* Patients deemed ineligible by the investigator.

Where it's running

• Sun Yat-sen Memorial Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Yinduo Zeng, MD — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Study coordinator: Tao Qin, MD
• Email: qintao5471@163.com
• Phone: 86-02034071337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Estimating Platelet Counts with ROTEM PLTEM in Laboring Women with Low Platelets or Heavy Bleeding

  This study tests whether the PLTEM value from ROTEM sigma testing can quickly estimate platelet count in pregnant women with low platelets or severe postpartum hemorrhage to help decisions about anesthesia and transfusions.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid · NCT07616349

• Etamsylate versus placebo to prevent bleeding after stem cell transplant

  This will test whether etamsylate can reduce bleeding in adults with very low platelets after hematopoietic stem cell transplantation.

  Recruiting Phase 3 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07442513

• Umbilical cord blood therapy for cancer treatment–related low platelets

  This trial will try an intravenous umbilical cord blood infusion to see if it raises platelet counts in people aged 12–65 with cancer treatment–induced thrombocytopenia.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07441720

• Umbilical cord blood-derived megakaryocyte injection for chemotherapy-related low platelets

  This single-dose treatment will try to raise platelet counts in adults with cancer who developed low platelets from anti-cancer therapy.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07110090

• Using apixaban to treat blood clots in cancer patients with low platelet counts

  This study is testing if a new dose of the blood thinner apixaban can safely help cancer patients with low platelet counts manage blood clots without causing more bleeding.

  Recruiting Early Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT06886516

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.